A controlled clinical study of serosa-invasive gastric carcinoma patients who underwent surgery plus intraperitoneal hyperthermo-chemo-perfusion (IHCP)
Authors:
- 14 June 2001
- journal article
- clinical trial
- Published by Springer Nature in Gastric Cancer
- Vol. 4 (1) , 27-33
Abstract
Despite recent advances in the treatment of advanced gastric carcinomas, no satisfactory outcomes are available because of micrometastases and free-floating carcinoma cells already existing in the peritoneal cavity. From 1990, we started using intraperitoneal hyperthermo-chemo-perfusion (IHCP) to prevent and to treat peritoneal metastasis after surgical resection of stomach cancer. Method. We analyzed 103 serosa-invasive gastric carcinoma patients who underwent surgical resection between 1990 and 1995. Fifty-two patients who received surgery plus IHCP were compared with 51 patients who underwent surgery only, as controls. IHCP was administered for 2 h with an automatic IHCP device (closed-circuit system) just after surgical resection, with the patient under hypothermic general anesthesia (32.4 °C–34.0 °C). As perfusate, we used 1.5% peritoneal dialysis solution mixed with 10 μg/ml of mitomycin-C (MMC), warmed at an inflow temperature of over 44 °C. Results. The overall 5-year survival rate (5-YSR) of the 103 patients was 29.97%. The 5-YSR was higher in the IHCP group than in the control group, at 32.7% and 27.1%, respectively, but this difference was not significant. However, in the 65 serosa-invasive gastric carcinoma patients (excluding those in stage IV) the 5-YSR was significantly higher (P = 0.0379) in the IHCP group than in the control group, at 58.6% and 44.4%, respectively. On multivariate analysis of all 103 patients, depth of tumor invasion and lymph node metastasis were significant factors for survival, whereas significant factors on univariate analysis, such as combined operation, distant metastasis, and peritoneal metastasis, were not significant. The most common recurrence patterns were loco-regional in the IHCP group and peritoneal in the control group. Conclusion. Complete cytoreductive surgery plus IHCP is effective to prevent and to treat peritoneal metastasis, and it should lead to long-term survival for serosa-invasive gastric carcinoma patients. However, there are some limitations for the treatment of peritoneal metastasis in stage IV patients with distant metastases.Keywords
This publication has 10 references indexed in Scilit:
- Prognostic value and clinical implications of disseminated cancer cells in the peritoneal cavity detected by reverse transcriptase-polymerase chain reaction and cytologyInternational Journal of Cancer, 1998
- Detection of Carcinoembryonic Antigen‐expressing Free Tumor Cells in Peritoneal Washes from Patients with Gastric Carcinoma by Polymerase Chain ReactionJapanese Journal of Cancer Research, 1997
- Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled studyCancer, 1994
- Carcinoembryonic antigen levels in peritoneal washings can predict peritoneal recurrence after curative resection of gastric cancerCancer, 1991
- Does extensive dissection of lymph nodes improve the results of surgical treatment of gastric cancer?The American Journal of Surgery, 1990
- Continuous hyperthermic peritoneal perfusion for the treatment of peritoneal dissemination in gastric cancers and subsequent second-look operationCancer, 1990
- Clinical trial with surgery and intraperitoneal hyperthermic perfusion for peritoneal recurrence of gastrointestinal cancerCancer, 1989
- Intraperitoneal Hyperthermic Perfusion Combined with Surgery Effective for Gastric Cancer Patients with Peritoneal SeedingAnnals of Surgery, 1988
- Progress in gastric cancer surgery in Japan and its limits of radicalityWorld Journal of Surgery, 1987
- Evaluation of extensive lymph node dissection for carcinoma of the stomachWorld Journal of Surgery, 1981